Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873040 | 0.86 | NR1H2 (0.41) | ITGB3ITGA2BDDB1CRBNNR1H2 | |
| SCHEMBL1583253 | 0.86 | P2RX7 (0.46) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL4005175 | 0.86 | NR1H2 (0.41) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL24744821 | 0.84 | NR1H2 (0.40) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL1176507 | 0.84 | NR1H2 (0.40) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL4390630 | 0.84 | NR1H2 (0.41) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL12495751 | 0.84 | ADORA1 (0.42) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL21520542 | 0.84 | DDB1 (0.39) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL6969188 | 0.83 | P2RX7 (0.49) | DDB1CRBNNR1H2USP2SMN1; SMN2 | |
| SCHEMBL1583540 | 0.83 | CNR2 (0.40) | DDB1CRBNNR1H2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
| EP-2681200-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals Ltd. (CA) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012116440-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | ITGB3 2300/4885ITGA2B 1927/4885DDB1 4279/4885 |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | HDAC5, HDAC1, HDAC3 | ITGB3 1349/4885ITGA2B 2209/4885DDB1 3178/4885 |
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | ITGB3 2262/4885ITGA2B 1849/4885DDB1 4286/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | ITGB3 2262/4885ITGA2B 1849/4885DDB1 4286/4885 |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | ITGB3 2300/4885ITGA2B 1927/4885DDB1 4279/4885 |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | ITGB3 2186/4885ITGA2B 1775/4885DDB1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.